Illumina, Inc. (ILMN) Management Presents at UBS MedTech, Tools and Genomics Summit 2023 Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) UBS MedTech, Tools and Genomics Summit 2023 Conference Transcript August 17, 2023 12:00 PM ET Executives Salli Schwartz - Vice President, Investor Relations Analysts J...
Down 15% in 2023, Should You Buy the Dip With Illumina Stock?
Illumina is facing a slew of issues due to a botched acquisition. It's also not growing very quickly.
SEC investigating Illumina over acquisition of cancer test developer Grail
Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.
US securities regulator probes Illumina over Grail deal
The U.S. Securities and Exchange Commission (SEC) has begun an investigation into Illumina's $7.1 billion acquisition of cancer detection test maker Grail , the gene sequencing company said in a re...
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
Illumina (ILMN) shipped 109 NovaSeq X instruments in the second quarter, boosting its supply capacity to more than 390 instruments for fiscal 2023.
Illumina Slashes Guidance Amid 'Cautious' Consumer. What Wall Street Thinks.
Citi analyst Patrick Donnelly cut his price target on Illumina to $150 from $180.
Illumina, Inc. (ILMN) Q2 2023 Earnings Call Transcript
Illumina, Inc. (NASDAQ:ILMN ) Q2 2023 Results Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Salli Schwartz - Vice President of Investor Relations Charles Dadswell - Interi...
Illumina (ILMN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compar...
Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates
Illumina (ILMN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.57 per share a year ago.
Illumina stock falls, as ‘cautious consumer backdrop' tempers outlook
Shares of Illumina Inc. slid 6.6% after hours on Wednesday after the DNA-sequencing company tempered its full-year sales outlook, amid a cautious consumer backdrop and a wobbly economic recovery in...
Illumina cuts annual profit forecast
Illumina Inc lowered annual profit forecast on Wednesday, signaling weak demand for its sequencing and diagnostic services, sending the life sciences firm's shares down 7.5% after the bell.
Related Companies